Pratik B. Sandesara

Pratik B. Sandesara

Auto-generated profile, based on publicly available information

Pratik B. Sandesara

Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2017 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
PSPratik B. Sandesara
Pratik B. Sandesara
WOWesley T. O’neal
Wesley T. O’neal
HKHeval M. Kelli
Heval M. Kelli
ASAyman Samman-Tahhan
Ayman Samman-Tahhan
MHMuhammad Hammadah
Muhammad Hammadah
LSLaurence S. Sperling
Laurence S. Sperling
OBJECTIVE This study examined the prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction (HFpEF). RESEARCH DESIGN AND METHODS This analysis included 3,385 patients (mean age 69 ± 9.6 years; 49% male; 89% white) with HFpEF from the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT). Diabetes and microvascular complications were ascertained by self-reported history and medical record review. Microvascular complications included neuropathy, nephropathy, and retinopathy. Outcomes included hospitalization, hospitalization for heart failure, death, and cardiovascular death. Cox regression was used to examine the risk of each outcome associated with diabetes and microvascular complications. RESULTS Of the 1,109 subjects (32%) with diabetes, 352 (32%) had at least one microvascular complication. Patients with diabetes and microvascular complications had an increased risk for hospitalization (no diabetes: referent; diabetes + no microvascular complication: hazard ratio [HR] 1.18, 95% CI 1.01, 1.37; diabetes + microvascular complications: HR 1.54, 95% CI 1.25, 1.89; P-trend <0.001), hospitalization for heart failure (no diabetes: referent; diabetes + no microvascular complication: HR 1.51, 95% CI 1.14, 1.99; diabetes + microvascular complications: HR 1.97, 95% CI 1.38, 2.80; P-trend <0.001), death (no diabetes: referent; diabetes + no microvascular complication: HR 1.35, 95% CI 1.04, 1.75; diabetes + microvascular complications: HR 1.73, 95% CI 1.22, 2.45; P-trend = 0.0017), and cardiovascular death (no diabetes: referent; diabetes + no microvascular complication: HR 1.34, 95% CI 0.96, 1.86; diabetes + microvascular complications: HR 1.70, 95% CI 1.09, 2.65; P-trend = 0.018). When the analysis was limited to participants who reported prior hospitalization for heart failure (n = 2,449), a higher risk of rehospitalization for heart failure was observed across diabetes categories (no diabetes: referent; diabetes + no microvascular complication: HR 1.40, 95% CI 1.01, 1.96; diabetes + microvascular complications: HR 1.78, 95% CI 1.18, 2.70; P-trend = 0.0036). CONCLUSIONS Diabetes is associated with adverse cardiovascular outcomes in HFpEF, and the inherent risk of adverse outcomes in HFpEF patients with diabetes varies by the presence of microvascular complications.

1 January 2020 in Atherosclerosis
Verified
Journal Article
Closed access
PSPratik B. Sandesara
Pratik B. Sandesara
AMAnurag Mehta
Anurag Mehta
WOWesley O'neal
Wesley O'neal
HKHeval M. Kelli
Heval M. Kelli
VSVasanth Sathiyakumar
Vasanth Sathiyakumar
LSLaurence S. Sperling
Laurence S. Sperling

1 October 2020 in The American Journal of Medicine
Verified
Journal Article
Closed access
MDMelroy S. D'SOuza
Melroy S. D'SOuza
TDTiffany Dong
Tiffany Dong
GRGabrielle Ragazzo
Gabrielle Ragazzo
DDDevinder S. Dhindsa
Devinder S. Dhindsa
AMAnurag Mehta
Anurag Mehta
LSLaurence Sperling
Laurence Sperling

1 July 2020 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
PSPratik B. Sandesara
Pratik B. Sandesara
AMAnurag Mehta
Anurag Mehta
WOWesley T. O’nEal
Wesley T. O’nEal
HKHeval Mohamed Kelli
Heval Mohamed Kelli
VSVasanth Sathiyakumar
Vasanth Sathiyakumar
LSLaurence S. Sperling
Laurence S. Sperling

2 August 2022 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
SKSpyridon Kostantinis
Spyridon Kostantinis
BSBahadir Simsek
Bahadir Simsek
JKJudit Karacsonyi
Judit Karacsonyi
RDRhian E. Davies
Rhian E. Davies
SBStewart Benton
Stewart Benton
EBEmmanouil Brilakis
Emmanouil Brilakis

4 September 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WOWesley O'neal
Wesley O'neal
AAAniqa Alam
Aniqa Alam
PSPratik B. Sandesara
Pratik B. Sandesara
JCJ’nEka S. Claxton
J’nEka S. Claxton
RMRichard F. MacLehose
Richard F. MacLehose
AAAlvaro Alonso
Alvaro Alonso
Outcomes among atrial fibrillation (AF) patients may differ according to race/ethnicity and sex due to differences in biology, the prevalence of cardiovascular risk factors, and the use and effectiveness of AF treatments. We aimed to characterize patterns of cardiovascular risk across subgroups of AF patients by sex and race/ethnicity, since doing so may provide opportunities to identify interventions. We also evaluated whether these patterns changed over time. We utilized administrative claims data from the Optum Clinformatics® Datamart database from 2009 to 2015. Patients with AF with ≥6 months of enrollment prior to the first non-valvular AF diagnosis were included in the analysis. Final analysis utilized Cox proportional hazard models to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI) for cardiovascular outcomes stratified by sex and race/ethnicity. An additional analysis stratified outcomes by calendar year of AF diagnosis to evaluate changes in outcomes over time. In a cohort of 380,636 AF patients, women had a higher risk of ischemic stroke [HR (95% CI): 1.25 (1.19, 1.31)] and lower risk of heart failure and myocardial infarction [HR (95% CI): 0.91 (0.88, 0.94) and 0.81 (0.77, 0.86), respectively)] compared to men. Black patients had elevated risk across all endpoints compared to whites, while Hispanics and Asian Americans showed no significant differences in any outcome compared to white patients. These sex and race/ethnic differences did not change over time. We found sex and race/ethnic differences in risk of cardiovascular outcomes among AF patients, without evidence of improvement over time.